XS-02 / Fosun Pharma - LARVOL DELTA

A Study of XS-02 Capsules in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=96 | Not yet recruiting | Sponsor: NovaOnco Therapeutics Co., Ltd.

Metastases • New P1/2 trial • Breast Cancer • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor

Discovery of a novel and oral CHK1 inhibitor for the treatment of solid tumors (AACR 2023) - "Others are related to their limited clinical efficacy, such as SRA737 which selectively inhibits CHK1 but not CHK2. Prexasertib (LY2606368), one of the few agents to undergo clinical trials, specifically inhibits both CHK1 and CHK2, displaying obvious therapeutic effects but also raising inevitable target-associated drug toxicities and a potential compliance issue due to intravenous administration...Moreover, the combination of XS-02 and olaparib, a PARP inhibitor, accelerated tumor regression, which synergy was confirmed in a patient-derived tumor xenograft animal model of acquired resistance to olaparib, without significant body weight changes...These results support the agent as a clinical candidate for the treatment of solid tumors. An Investigational New Drug application is planned for 2023."

Oncology • Solid Tumor